a specific microenvironment that decides the fate of progenitor cells. [15] [16] [17] [18] [19] [20] Therefore, it is important to investigate the effects of vessels on tissue regeneration. CD31 hi EMCN hi vessels (CD31, also known as PECAM1 [platelet and endothelial cell adhesion molecule 1]; EMCN, endomucin), which are strongly positive for CD31 and endomucin, are specific vessels in the skeletal system that couple angiogenesis and osteogenesis. 18 Our previous studies demonstrated that inducing CD31 hi EMCN hi vessels could stimulate bone formation. [21] [22] [23] Angiogenesis coupled with osteogenesis plays an important role in bone metabolism; however, the role of CD31 hi EMCN hi vessels in bone regeneration remains unknown.
Our previous study demonstrated that mutant REG1CP (regenerating family member 1 gamma) increased the formation of the CD31 hi Emcn hi endothelium in bone marrow by binding to Krüppellike factor 3 (KLF3) to inhibit its activity. We also identified a natural compound, ophiopogonin D, which functions as a KLF3 inhibitor. 23 Administration of ophiopogonin D increased the abundance of CD31 hi Emcn hi vessels and bone formation. 23 In the present study, we expanded our research and demonstrated that ophiopogonin D acts as a KLF3 inhibitor to promote vessel formation and further stimulate bone regeneration in young (3 months old) and middle-aged (12 months old) mice.
| MATERIAL S AND ME THODS

| Mice
To specific knockout Klf3 in endothelium, we crossed mice carrying were purchased from Jackson Laboratory, and loxP-flanked Klf3 mice were purchased from Cyagen Biosciences Inc (China). The bone regeneration model was established as described before. 24, 25 A longitudinal incision was made on each knee to expose the femoral condyle by patella dislocation. Then, we used a dental drill to make a hole was at the intercondylar notch of the femur. A 0.6-mm-diameter Kirschner wire was placed from the proximal end of the femur. We confirmed the bone ablation of trabecular bone by radiography. Bone samples were collected 1 week after the surgery. For ophiopogonin D treatment experiment, mice under surgical ablation of trabecular bone were intraperitoneally treated with ophiopogonin D at dosage of 20 mg/kg every day for 7 days. All mice we used were C57BL/6J background.
Male mice at indicated age were used in our experiments. All mice were maintained in standard, specific pathogen-free facility of the Laboratory Animal Research Center of Central South University.
| Isolate primary BMSCs
We isolated primary BMSCs as reported previously. 26, 27 We collected all bone marrow cells and incubated them with FITC-, APC-and PE-conjugated antibodies which recognized mouse Sca-1 (BioLegend, 108108), CD29 (BioLegend, 102206), CD45 (BioLegend, 103132) and CD11b (BioLegend, 101226) for 30 minutes at 4°C. Then, we performed fluorescence-activated cell sorting (FACS) and analysis the results using FACS DIVE software version 6.1.3 (BD Biosciences). The sorted mouse Sca-1 + CD29 + CD45 − CD11b − BMSCs were cultured with α-MEM (Gibco-BRL Co.) supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin.
| Osteogenic differentiation assay
Isolated BMSCs were cultured with α-MEM (Gibco-BRL Co.) supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 0.1 mmol/L dexamethasone, 10 mmol/L b-glycerol phosphate and 50 mmol/L ascorbate-2-phosphate for 21 days. Culture medium was changed every three days. Cells were collected for RNA extraction or stained with 2% Alizarin Red S (Sigma-Aldrich) at pH 4.2 to evaluate the cell matrix mineralization.
| Osteoclasts differentiation assay
Osteoclasts differentiation assay was performed as reported previously. 28 Monocytes and macrophages were collected from bone marrow of mice by flushing the marrow space of femora and tibiae.
The isolated bone marrow cells were cultured with α-MEM (Gibco-BRL Co.) supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/ mL streptomycin for 12 hours; then, the floating cells were cultured with α-MEM (Gibco-BRL Co.) supplemented with 10% FBS, 100 U/ mL penicillin, 100 μg/mL streptomycin and 30 ng/mL M-CSF (R&D Systems Inc) for 3 days to obtain pure monocytes and macrophages.
Then, these cells were cultured with α-MEM (Gibco-BRL Co.) supplemented with 10% FBS, 100 U/mL penicillin, 100 μg/mL streptomycin, 30 ng/mL M-CSF and 60 ng/mL RANKL (PeproTech) for 8 days. Cells were collected for RNA extraction or stained with TRAP (Sigma-Aldrich). 
| Migration assay
| Tube formation assay
Tube formation assay was performed as reported previously. 29 Endothelial cell tube formation assay was conducted in 48-well plates precoated with Matrigel (BD). 1 × 10 5 cells were seeded per well after 1-hour serum starvation. After 5-, 7-, 9-and 12-hour incubation at 37°C, the tube formation of HMECs was observed and the number of tube branches was quantified by counting 4 random microscope visual fields in each well.
| Wound healing assay
Human microvascular endothelial cells or BMSCs were grown to confluency. A linear wound was made by scraping a non-opening Pasteur pipette across the confluent cell layer. 5, 7, 9 and 12 hours after wound, the migrate cells were observed and measured by counting 4 random microscope visual fields in each well.
| qRT-PCR analysis
Total RNA from cells was extracted using TRIzol reagent (Invitrogen). 
| Western blot
| Flow cytometry
We isolated femora and tibia from mice, then crushed the metaphysis region in ice-cold PBS. Bone pieces were digested using 1 mg/mL type I A collagenase at 37°C for 20 minutes to obtain single-cell suspensions. Then, the cells were counted and incubated for 45 minutes at 4°C with endomucin antibody (Santa Cruz, SC-65495, 1:100) and APC-conjugated CD31 antibody (R&D Systems, FAB3628A, 1:100). We performed acquisition on a fluorescence-activated cell sorting (FACS) FACScan cytometer (BD Immunocytometry Systems).
| μCT analysis
We used the high-resolution μCT (Skyscan 1172, Bruker microCT, Kontich, Belgium) to perform the µCT analysis. The scanner was set at a voltage of 65 kV, a current of 153 μA and a resolution of 15 μm per pixel. We used the image reconstruction software (NRecon, ver- 
| Histochemistry
Histochemistry staining was performed as reported previously. 30, 31 Femora were dissected from mice. After fixing overnight with 10% formalin at 4°C, the samples were decalcified at 4°C using 10% EDTA (pH 7.4) for 21 days and then embedded in paraffin. Fourmicrometre-thick femora were used for staining. The slides were processed for TRAP, and HE staining was performed using a standard protocol (Sigma-Aldrich).
| Immunocytochemistry
Immunocytochemistry staining was performed as reported previously. 32 Femora were dissected from mice. After fixing overnight with 10% formalin at 4°C, the samples were decalcified at 4°C using 10% EDTA (pH 7.4) for 21 days and then embedded in paraffin. Four-micrometre-thick femora were used for staining. The slides were stained with individual primary antibodies to OCN (Takara Bio Inc M137) at 4°C overnight. Horseradish peroxidasestreptavidin detection system (Dako) was used to detect immunoactivity. Then, we counterstained the sections with haematoxylin (Sigma-Aldrich).
| Immunofluorescence
Immunofluorescence staining was performed as reported previously. 33, 34 Femora were dissected from mice. After fixing with ice-cold 4% paraformaldehyde solution for 4 hours, the samples were decalcified in 0.5 mol/L EDTA (pH 7.4) at 4℃ for 24 hours (1and 3-month-old mice) or for 48 hours (12-month-old mice). The bone samples were then incubated in 20% sucrose and 2% polyvinylpyrrolidone (PVP) solution overnight, as described previously. 35 For CD31 hi EMCN hi vessels staining, the tissues were embedded 
| Statistics
The data are presented as the mean ± SD; For comparisons of two groups, two-tailed Student's t test was used. For comparisons of multiple groups, one-way ANOVA was used. Differences were considered significant at P < .05. No randomization or blinding was used, and no animals were excluded from analysis. Sample sizes were selected on the basis of previous experiments. 
| Study approval
| RE SULTS
| The amount of CD31 hi EMCN hi vessels decreased during ageing but increased in bone regeneration
As animals age, the decrease in the number of osterix-positive (OSX + ) osteoprogenitors and bone mass correlates with the pronounced reduction in CD31 hi Emcn hi vessels ( Figure 1A -C and G-H). The amount of CD31 hi Emcn hi vessels, which mainly appear in the metaphysis just below the growth plate in 1 month old, was significantly decreased in adults (3 months old) and was nearly absent in aged (12 months old) mice ( Figure 1A,B ). Flow cytometry analysis confirmed the age-dependent reduction of CD31 hi Emcn hi endothelial cells ( Figure 1D,E) . To investigate the role of CD31 hi EMCN hi vessels in bone regeneration, we constructed a bone regeneration model after surgical ablation of the trabecular bone. 24, 25 We found that abundant CD31 hi EMCN hi vessels, as well as alkaline phosphatasepositive (ALP + ) osteoprogenitors and OSX + osteoprogenitors, emerged in the bone regeneration area in the 3-month-old mice at 1 week after surgery ( Figure 1F and Figure S1 ). The amount of CD31 hi EMCN hi vessels in the femur of the 12-month-old mice was also increased at 1 week after trabecular bone ablation ( Figure 1F ).
The bone volume in the regeneration area was increased together
with the number of CD31 hi EMCN hi vessels and osteoprogenitors cells ( Figure 1G -H and Figure S1 ). These results indicated that the CD31 hi EMCN hi vessels might play an important role in bone regeneration. 
| Endothelial-specific Klf3 knockout mice show increased numbers CD31 hi EMCN hi vessel and accelerated bone regeneration
| Ophiopogonin D acts as a KLF3 inhibitor and promotes vessels formation in vitro
Our previous research demonstrated that KLF3 represses the expression of JUNB (JunB proto-oncogene, AP-1 transcription factor subunit) as well as its downstream factor VEGFA (vascular endothelial growth factor A) in endothelial cells, and further inhibited the process of angiogenesis. 23 We also identified a natural compound from Radix Ophiopogon japonicus, ophiopogonin D, which acts as a KLF3 inhibitor to abolish the transcriptional repression function of KLF3 and further increase the expression of JUNB and VEGFA in endothelial cells. 23 As expected, we observed that CD31, EMCN, and JUNB and vessel growth factors (VEGFA, VEGFB, PDGFA (platelet derived growth factor subunit A), and PDGFB) transcripts were expressed at higher level in human microvascular endothelial cells (HMECs) treated with ophiopogonin D compared with that in DMSO control treated HMECs ( Figure 3A-G) . Chromatin immunoprecipitation-PCR (ChIP-PCR) assays showed that ophiopogonin D treatment affected the binding of KLF3 to the promoter of JUNB. 23 Western blotting also showed increased protein levels of JUNB and VEGFA in HMECs treated with ophiopogonin D, without affect the expression of KLF3 ( Figure 3H ). We further confirmed the angiogenesis stimulating function of ophiopogonin D using migration and tube formation assays. The results showed that ophiopogonin D treatment could increase the migration and tube formation ability of HMECs ( Figure 3I-N) . These data demonstrated that ophiopogonin D works as a KLF3 inhibitor and has a positive effect on angiogenesis in vitro.
| Ophiopogonin D does not affect BMSC migration and osteoblastic differentiation in vitro
To investigate the role of ophiopogonin D in bone formation in vitro, we isolated primary bone marrow-derived stem cells (BMSCs) and carried out migration and osteogenic differentiation assays. Alizarin Red staining showed no difference between the ophiopogonin D and DMSO control treatment groups in the BMSC osteogenic differentiation assays ( Figure 4A ). The expression levels of the osteoblastic markers Runx2 (RUNX family transcription factor 2), Alp (alkaline phosphatase) and Sp7 (SP7 transcription factor) remained unchanged after ophiopogonin D treatment 
| Ophiopogonin D treatment promotes CD31 hi EMCN hi vessel and bone formation during bone regeneration
To investigate whether treatment with ophiopogonin D could promote CD31 hi EMCN hi vessel formation and further stimulate bone regeneration in vivo, 3-month-old and 12-month-old C57BL/6J mice, after surgical ablation of the trabecular bone, were treated intraperitoneally with ophiopogonin D at 20 mg/kg every day for 1 week.
This treatment did not affect the body weight of either group of mice ( Figure 5A and Figure S3A ) 
| D ISCUSS I ON
Blood vessels play an important role in tissue regeneration by recruiting progenitor cells. [36] [37] [38] [39] In skeleton tissue, CD31 hi EMCN hi vessels generate distinct metabolic and molecular microenvironments, maintain perivascular osteoprogenitors and couple angiogenesis to osteogenesis. 18, 40 Osteoblast derived Slit guidance ligand 3 (SLIT3) could increase the formation of the CD31 hi EMCN hi endothelium.
Pre-osteoclasts could induce the CD31 hi EMCN hi vessel subtype, subsequently preventing bone loss in osteoporosis. 21 Our previous study revealed that the microRNA miR-497∼195 cluster contributes to the increase in CD31 hi EMCN hi vessels and bone formation in aged mice. 22 cardiac development. [41] [42] [43] [44] [45] JunB is one of the KLF3 downstream genes and acts as a critical regulator of Vegfa. [46] [47] [48] Our previous studies have shown that KLF3 inhibited the expression of JUNB and VEGFA, and further repressed angiogenesis. 23 We also demonstrated that specific knockout of Klf3 in endothelial cells increased the formation of CD31 hi EMCN hi vessels and increased bone formation. 23 Here, we extended our study and confirmed that specific knockout of Klf3 in endothelial cells also could stimulate CD31 hi EMCN hi vessel formation after bone injury and could accelerate bone regeneration.
Ophiopogonin D is a natural compound isolated from the traditional Chinese herbal agent Radix Ophiopogon japonicus, 49 which showed anti-osteoporotic effects in a murine ovariectomized (OVX) model. 50 Previously, we identified that ophiopogonin D could bind to KLF3 and suppress its function, thus further promoting angiogenesis. 23 In the present study, we further demonstrated that ophiopogonin D also could increase CD31 hi EMCN hi vessel formation and bone regeneration after bone injury.
In summary, we revealed the important role of CD31 hi EMCN hi vessels in bone regeneration and demonstrated the natural compound ophiopogonin D could increase the number of CD31 hi EMCN hi vessels and promoted bone regeneration after bone injury. Our findings provide a potentially novel strategy to accelerate bone healing.
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